Gilead Sciences Profile

USD 0.32  0.41%

Sale by John Martin of 214707 shares of Gilead Sciences

Gilead Sciences insider trading alert for sale of common stock by John Martin, Chairman and CEO, on July 21, 2018. This event was filed by Gilead Sciences Inc with SEC on 2013-03-05. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Gilead Sciences Summary

Gilead Sciences made a $10 billion bet and lost.? They invested heavily into a drug that was denied release by the FDA.? Naturally, the stock was sold off sharply.? While the stock was sitting at highs of nearly $50.00, it is now a mere 10% of the level now.? But, just because the stock is beaten down as it is, does that mean it is a bad bet? ? [more]
Gilead Sciences (GILD) is traded on BATS Exchange in USA. It is located in CALIFORNIA U.S.A and employs 10,000 people. Gilead Sciences is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Mega-Cap' category with current market capitalization of 100.28 B. Gilead Sciences conducts business under Healthcare sector and is part of Pharmaceuticals And Biosciences industry. This company has 1.3 B outstanding shares of which 16.31 M shares are currently shorted by private and institutional investors with about 2.29 trading days to cover. GILEAD SCIENCES currently holds about 24.68 B in cash with 9.75 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 18.98.
Check Gilead Sciences Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 77.05HorizonTargetOdds Above 77.05
83.85%30 days 77.05 15.98%
Based on normal probability distribution, the odds of Gilead Sciences to move above current price in 30 days from now is about 15.98% (This Gilead Sciences probability density function shows the probability of Gilead Sciences Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Bank Of MontrealCommon Shares2.6 M181.1 M
SwedbankCommon Shares1.9 M135.8 M
View Gilead Sciences Diagnostics

Selected Gilead Sciences Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Gilead Sciences Against Markets

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Gilead Sciences are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 10000 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Gilead Sciences SEC Filings
Gilead Sciences SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameGilead Sciences
Chairman and CEOJohn MartinView All
Thematic Classification
Currently Active Investing Idea
  Macroaxis Index
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Bond Rating
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
Business Address333 Lakeside Drive
Foreign Associates
ExchangeBATS Exchange
CIK Number0000882095
IndustryPharmaceuticals And Biosciences
Phone650 574 3000
CurrencyUSD - US Dollar

Did you try this?

Run Price Transformation Now

Price Transformation

Use Price Transformation models to analyze depth of different equity instruments across global markets
All  Next Launch Price Transformation

Gilead Sciences Corporate Directors

Gayle Wilson Independent Director
Jacqueline Barton Director
John Madigan Independent Director
Please also check Risk vs Return Analysis. Please also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.